Literature DB >> 21945284

Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases.

Gisele A Nishiguchi1, Gordana Atallah, Cornelia Bellamacina, Matthew T Burger, Yu Ding, Paul H Feucht, Pablo D Garcia, Wooseok Han, Liana Klivansky, Mika Lindvall.   

Abstract

A series of novel 3,5-disubstituted indole derivatives as potent and selective inhibitors of all three members of the Pim kinase family is described. High throughput screen identified a pan-Pim kinase inhibitor with a promiscuous scaffold. Guided by structure-based drug design, SAR of the series afforded a highly selective indole chemotype that was further developed into a potent set of compounds against Pim-1, 2, and 3 (Pim-1 and Pim-3: IC(50)≤2nM and Pim-2: IC(50)≤100nM).
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945284     DOI: 10.1016/j.bmcl.2011.08.105

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.

Authors:  Mustapha Haddach; Jerome Michaux; Michael K Schwaebe; Fabrice Pierre; Sean E O'Brien; Cosmin Borsan; Joe Tran; Nicholas Raffaele; Suchitra Ravula; Denis Drygin; Adam Siddiqui-Jain; Levan Darjania; Ryan Stansfield; Chris Proffitt; Diwata Macalino; Nicole Streiner; Joshua Bliesath; May Omori; Jeffrey P Whitten; Kenna Anderes; William G Rice; David M Ryckman
Journal:  ACS Med Chem Lett       Date:  2011-12-27       Impact factor: 4.345

2.  Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.

Authors:  Matthew T Burger; Wooseok Han; Jiong Lan; Gisele Nishiguchi; Cornelia Bellamacina; Mika Lindval; Gordana Atallah; Yu Ding; Michelle Mathur; Chris McBride; Elizabeth L Beans; Kristine Muller; Victoriano Tamez; Yanchen Zhang; Kay Huh; Paul Feucht; Tatiana Zavorotinskaya; Yumin Dai; Jocelyn Holash; Joseph Castillo; John Langowski; Yingyun Wang; Min Y Chen; Pablo D Garcia
Journal:  ACS Med Chem Lett       Date:  2013-10-15       Impact factor: 4.345

3.  Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.

Authors:  Rand Shahin; Lubna Swellmeen; Omar Shaheen; Nour Aboalhaija; Maha Habash
Journal:  J Comput Aided Mol Des       Date:  2015-12-19       Impact factor: 3.686

4.  Flexibility of the P-loop of Pim-1 kinase: observation of a novel conformation induced by interaction with an inhibitor.

Authors:  Lorien J Parker; Hisami Watanabe; Keiko Tsuganezawa; Yuri Tomabechi; Noriko Handa; Mikako Shirouzu; Hitomi Yuki; Teruki Honma; Naoko Ogawa; Tetsuo Nagano; Shigeyuki Yokoyama; Akiko Tanaka
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-07-31

Review 5.  Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.

Authors:  Ying-Yi Li; Naofumi Mukaida
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

6.  A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.

Authors:  Jason M Foulks; Kent J Carpenter; Bai Luo; Yong Xu; Anna Senina; Rebecca Nix; Ashley Chan; Adrianne Clifford; Marcus Wilkes; David Vollmer; Benjamin Brenning; Shannon Merx; Shuping Lai; Michael V McCullar; Koc-Kan Ho; Daniel J Albertson; Lee T Call; Jared J Bearss; Sheryl Tripp; Ting Liu; Bret J Stephens; Alexis Mollard; Steven L Warner; David J Bearss; Steven B Kanner
Journal:  Neoplasia       Date:  2014-06-18       Impact factor: 5.715

7.  PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.

Authors:  Fabiola Cervantes-Gomez; Christine M Stellrecht; Mary L Ayres; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Oncotarget       Date:  2019-04-19

8.  PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients.

Authors:  Athina Markou; Eleni Tzanikou; Areti Strati; Martha Zavridou; Sophia Mastoraki; Evangelos Bournakis; Evi Lianidou
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.